Whether voclosporin has been covered by medical insurance and the latest reimbursement policy and cost description

Voclosporin (Voclosporin), as a new type of cyclosporine immunosuppressant, has not yet been officially launched in China, and therefore has not been included in the national medical insurance (medical insurance) catalog. This means that domestic patients cannot obtain the drug through medical insurance reimbursement for the time being, and can only rely on purchasing drugs overseas or participating in clinical studies. Since the drug has not yet been launched on the market, the specific policy regarding its future inclusion in domestic medical insurance has not yet been clarified. Therefore, patients and medical institutions are still paying attention to the progress of import, approval and medical insurance negotiations.

In overseas markets, Voclosporin has been approved by many countries for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis. Taking the European version as an example, the reference price of each box of the original drug with the specification of 7.9 mg*180 capsules is approximately 1.6 RMB, but this price will fluctuate with exchange rate fluctuations, sales channels and tax policies. Since this is an original drug and an imported product, its price is generally high. Coupled with additional costs such as cross-border transportation and import taxes, some patients bear a heavy burden.

It is worth noting that there are currently no generic versions of Voclosporin widely available worldwide. This also means that overseas patients mainly rely on original drugs, and domestic substitution has not yet appeared. Therefore, purchasing drugs overseas not only imposes a heavy financial burden on domestic patients, but also issues such as transportation, compliance, and safety need to be fully considered. Drug accessibility remains an important constraint, and if patients purchase drugs across borders, they need to carefully choose formal and legal channels and consider the cost sustainability of long-term treatment.

In general, Voclosporin is not currently on the market in China, nor is it included in medical insurance. If domestic patients need this drug, it cannot currently be reimbursed through local medical insurance. Although purchasing overseas is feasible, it is more expensive and risky. In the future, if Voclosporin is approved in China and entered into the medical insurance catalog, it will significantly reduce the drug burden on patients; before then, patients in need should cooperate with professional doctors and international drug suppliers with legal qualifications through formal channels to ensure the safety of drug sources and financial support.

Reference materials:https://www.drugs.com/